Abraham N. Oler - 07 Feb 2022 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)

Reporting relationship: SVP Corp Dev & Gen Counsel
Issuer ticker: TRAW
Reported as of: 07 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2022, 15:38:57 UTC
Prior SEC filing: 31 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Mark Guerin as attorney-in-fact

Key filing fact

Abraham N. Oler filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 09 Feb 2022.

Key facts

This page summarizes Abraham N. Oler's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Feb 2022, 15:38.

Change

Previous filing in this sequence was filed on 31 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONTX transaction Derivative

Stock Option (right to purchase)

Award

Transaction value: $0
Shares: +54,050
Change %
Price: $0.000000
Shares after: 54,050
Date: 07 Feb 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 54,050
Exercise price: $1.82
Footnotes: F1

ONTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +17,633
Change %
Price: $0.000000
Shares after: 17,633
Date: 07 Feb 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 17,633
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

Footnote F2

These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.

Footnote F3

Each restricted stock unit is convertible into one share of common stock.